Table 1.

NEPA effectiveness and ORs considered in the model

.			Effectiveness	NEPA versus
			NEPA	APR + PALO	PALO*,†	APR + ONDA†
HEC	Acute phase	Complete response	92.8	1.952‡	7.540	3.602
		Complete protection	90.0	2.536‡	4.619	3.753
	Overall phase	Complete response	83.6	1.982‡	2.647	1.333
		Complete protection	78.0	2.064‡	2.102	1.345
MEC	Acute phase	Complete response	95.7	0.956‡	1.345	N/A
		Complete protection	92.8	1.099‡	1.084	N/A
	Overall phase	Complete response	88.1	1.248‡	1.450	N/A
		Complete protection	83.5	1.336‡	1.281	N/A

Due to the clinical non-inferiority of fAPR compared with APR and to a lack of data referred to therapies that imply the use of fAPR, the same ORs of APR based therapies were considered for fAPR + PALO and fAPR + ONDA.

*Considered for the budget impact analysis.

†HEC: data calculated on the basis of the results from reference [11]; MEC: data calculated on the basis of the results of reference [12].

‡Data calculated on the basis of the results from reference [15].

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron.